Patents by Inventor Israel Vlodavsky

Israel Vlodavsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190219601
    Abstract: The present invention relates to an inhibitory peptide capable of disrupting a Heparanase/Tissue Factor complex. The invention further provides methods and kits for determining heparanase procoagulant activity in a biological sample. The invention also relates to diagnostic methods for the detection and/or monitoring of a coagulation-related pathologic disorder in a mammalian subject. The invention further relates to compositions comprising heparanase and at least one tissue factor, uses and methods based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions. The invention still further relates to methods for screening a coagulation modulatory compound, methods and uses based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions.
    Type: Application
    Filed: April 4, 2019
    Publication date: July 18, 2019
    Inventors: Yona Nadir, Benjamin Brenner, Israel Vlodavsky
  • Patent number: 10302662
    Abstract: Methods and kits for determining heparanase procoagulant activity in a biological sample are provided. Diagnostic methods for the detection and/or monitoring of a coagulation-related pathological disorder in a mammalian subject are further provided. In addition, compositions comprising heparanase and at least one tissue factor, uses and methods based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions are provided. Also provided are methods for screening a coagulation modulatory compound, methods and uses based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: May 28, 2019
    Assignee: RAMBAM MED-TECH
    Inventors: Yona Nadir, Benjamin Brenner, Israel Vlodavsky
  • Publication number: 20190112391
    Abstract: The present invention relates to heparanase-neutralizing monoclonal antibodies (m Abs), pharmaceutical composition comprising same, and use thereof for treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, diabetes and related complications. The present invention further provides combined therapies comprising the heparanase-neutralizing m Ab and an anti-cancer treatment such as chemotherapy or radiation, for treating a proliferative disease in a subject.
    Type: Application
    Filed: October 13, 2016
    Publication date: April 18, 2019
    Applicant: Technion Research & Development Foundation Limited
    Inventors: Israel VLODAVSKY, Marina WEISSMANN, Neta ILAN, Gil ARVATZ
  • Publication number: 20160334425
    Abstract: Methods and kits for determining deparanase procoagulant activity in a biological sample. Diagnostic methods for the detection and/or monitoring of a coagulation-related pathological disorder in a mammalian subject. Compositions comprising heparanase and at least one tissue factor, uses and methods based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions. Methods for screening a coagulation modulatory compound, methods and uses based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions.
    Type: Application
    Filed: May 16, 2016
    Publication date: November 17, 2016
    Inventors: Yona Nadir, Benjamin Brenner, Israel Vlodavsky
  • Patent number: 9428586
    Abstract: The present invention, in at least some aspects, is of splice variants of heparanase, as well as diagnostic kits and methods of use, and therapeutic agents and methods of use based thereon, and antibodies specifically binding thereof.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: August 30, 2016
    Assignee: COMPUGEN LTD
    Inventors: Ronen Shemesh, Michal Ayalon-Soffer, Zurit Levine, Sergey Nemzer, Tomer Zekharya, Gad S. Cojocaru, Uri Barash, Neta Ilan, Israel Vlodavsky, Iris Hecht
  • Patent number: 9366684
    Abstract: The present invention relates to methods and kits for determining heparanase procoagulant activity in a biological sample. The invention also relates to diagnostic methods for the detection and/or monitoring of a coagulation-related pathologic disorder in a mammalian subject. The invention further relates to compositions comprising heparanase and at least one tissue factor, uses and methods based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions. The invention still further relates to methods for screening a coagulation modulatory compound, methods and uses based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: June 14, 2016
    Assignee: RAMBAM MED-TECH
    Inventors: Yona Nadir, Benjamin Brenner, Israel Vlodavsky
  • Patent number: 8853387
    Abstract: The present invention is directed to sulfated oligosaccharides having 4, 5 or 6 saccharidic units and wherein a glycosidic bond between two saccharide units is substituted by a C—C bond, and wherein the sulfation degree expressed as percentage of OH groups substituted by a OSO3? group is comprised between 50 and 100%. The sulfated oligosaccharides according to the invention are useful as a drug, in particular in the treatment of angiogenesis, metastasis, and inflammation.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: October 7, 2014
    Assignee: Istituto di Ricerche Chimiche e Biochimiche “G. Ronzoni”
    Inventors: Giangiacomo Torri, Elena Vismara, Israel Vlodavsky, Annamaria Naggi
  • Patent number: 8809620
    Abstract: The invention relates to cells and transgenic non-human mammals having at least one disrupted heparanase allele. The invention further relates to methods of screening therapeutic drug candidates utilizing the heparanase deficient non-human mammals and cells.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: August 19, 2014
    Assignee: Shenzhen Hepalink Pharmaceutical Co., Ltd.
    Inventors: Jin-ping Li, Ulf Lindahl, Israel Vlodavsky, Eyal Zcharia
  • Publication number: 20140140977
    Abstract: The present invention relates to methods and kits for determining heparanase procoagulant activity in a biological sample. The invention also relates to diagnostic methods for the detection and/or monitoring of a coagulation-related pathologic disorder in a mammalian subject. The invention further relates to compositions comprising heparanase and at least one tissue factor, uses and methods based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions. The invention still further relates to methods for screening a coagulation modulatory compound, methods and uses based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions.
    Type: Application
    Filed: January 18, 2012
    Publication date: May 22, 2014
    Inventors: Yona Nadir, Benjamin Brenner, Israel Vlodavsky
  • Publication number: 20120301475
    Abstract: The present invention, in at least some aspects, is of splice variants of heparanase, as well as diagnostic kits and methods of use, and therapeutic agents and methods of use based thereon, and antibodies specifically binding thereof.
    Type: Application
    Filed: November 30, 2010
    Publication date: November 29, 2012
    Inventors: Ronen Shemesh, Michal Ayalon-Soffer, Zurit Levine, Sergey Nemzer, Tomer Zekharya, Gad S. Cojocaru, Uri Barash, Neta Ilan, Israel Vlodavsky, Iris Hecht
  • Publication number: 20120232263
    Abstract: The present invention is directed to sulfated oligosaccharides having 4, 5 or 6 saccharidic units and wherein a glycosidic bond between two saccharide units is substituted by a C—C bond, and wherein the sulfation degree expressed as percentage of OH groups substituted by a OSO3? group is comprised between 50 and 100%. The sulfated oligosaccharides according to the invention are useful as a drug, in particular in the treatment of angiogenesis, metastasis, and inflammation.
    Type: Application
    Filed: July 9, 2009
    Publication date: September 13, 2012
    Applicant: Istituto Scientifico Di Chimica E Biochimica "G" R
    Inventors: Giangiacomo Torri, Elena Vismara, Israel Vlodavsky, Annamaria Naggi
  • Patent number: 8093031
    Abstract: The invention relates to novel heparanases, heparanase splice variants, and to polynucleotides encoding them. Particularly, the invention relates to Spalax heparanases, and to Spalax and human heparanase splice variants. Heparanase splice variants can be used, for example, to modulate the activity of heparanase in diseases disorders or conditions caused by or associated with the enzymatic activity of heparanase. For instance, a splice variant capable of down regulating the activity of heparanase can be used to treat primary tumors and/or to prevent or treat metastasis.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: January 10, 2012
    Assignee: Carmel-Haifa University Economic Corp. Ltd.
    Inventors: Nicola J. Nasser, Aaron Avivi, Israel Vlodavsky, Eviatar Nevo
  • Patent number: 8048993
    Abstract: According to the present invention there is provided an antibody that specifically binds an epitope of a heparanase protein, the heparanase protein including an amino acid sequence as set forth in SEQ ID NO:2, provided that phenylalanine replaces tyrosine at position 246. The present invention also provides an antibody elicited by an epitope of a heparanase protein, the heparanase protein including an amino acid sequence as set forth in SEQ ID NO:2, provided that phenylalanine replaces tyrosine at position 246.
    Type: Grant
    Filed: January 4, 2008
    Date of Patent: November 1, 2011
    Assignees: InSight Biopharmaceuticals Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Iris Pecker, Israel Vlodavsky, Yael Friedmann, Tuvia Peretz
  • Publication number: 20110104140
    Abstract: The present invention relates to inhibition of heparinoids anti-coagulation activity by a non-active form of a eukaryotic endoglycosidase or any fragment or peptide thereof comprising at least one heparin-binding domain. More particularly, the invention provides compositions and methods for the inhibition of heparinoids anti-coagulation activity and for the treatment of coagulation related pathologic clinical conditions, using a non-active form of mammalian heparanase or peptides thereof comprising at least one heparin-binding domain.
    Type: Application
    Filed: May 10, 2007
    Publication date: May 5, 2011
    Inventors: Israel Vlodavsky, Neta Ilan, Flonia Levy-Adam, Ben-Zion Katz
  • Patent number: 7790376
    Abstract: Heparanase specific molecular probes which can be used for detection of the presence, absence or level of heparanase expression and methods of utilizing same are provided.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: September 7, 2010
    Assignees: InSight Biopharmaceuticals Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Iris Pecker, Israel Vlodavsky, Yael Friedmann, Tuvia Peretz
  • Patent number: 7772187
    Abstract: An amino acid sequence derived from the N? terminus region of the 50 Kd subunit of heparanase, preferably, the sequence including amino acid residues Lys158-Asn171 of human heparanase and any functional fragments thereof. Compositions for the inhibition of heparanase glycosidase catalytic activity, having as an active ingredient an isolated and purified peptide as the amino acid sequence. An antibody directed to the sequence and compositions and uses thereof as heparanase inhibitor. The use of the amino acid sequence in a screening method for specific heparanase inhibitors. Compositions including the heparanase inhibitors and methods for the treatment of heparanase related disorders.
    Type: Grant
    Filed: July 28, 2004
    Date of Patent: August 10, 2010
    Assignees: Hadasit Medical Research Services and Development Company, Ltd., Rappaport Family Institute for Research in the Medical Sciences
    Inventors: Israel Vlodavsky, Neta Ilan, Flonia Levy-Adam
  • Patent number: 7666651
    Abstract: A polynucleotide (hpa) encoding a polypeptide having heparanase activity, vectors including same, genetically modified cells expressing heparanase, a recombinant protein having heparanase activity and antisense oligonucleotides and constructs for modulating heparanase expression.
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: February 23, 2010
    Assignees: InSight Biopharmaceuticals Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Iris Pecker, Israel Vlodavsky, Elena Feinstein
  • Publication number: 20090275106
    Abstract: A polynucleotide (hpa) encoding a polypeptide having heparanase activity, vectors including same, genetically modified cells expressing heparanase, a recombinant protein having heparanase activity and antisense oligonucleotides and constructs for modulating heparanase expression.
    Type: Application
    Filed: October 30, 2007
    Publication date: November 5, 2009
    Applicants: Insight Strategy & Marketing Ltd., Hadasit Maedical Research Services and Development Ltd.
    Inventors: Iris Pecker, Israel Vlodavsky, Elena Feinstein
  • Publication number: 20090099341
    Abstract: A variety of heparanase specific molecular probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase; the use of a heparanase specific molecular probe for quantification of heparanase in a body fluid; the use of a heparanase specific molecular probe for targeted drug delivery; and the use of a heparanase specific molecular probe as a therapeutic agent.
    Type: Application
    Filed: January 4, 2008
    Publication date: April 16, 2009
    Applicants: InSight Biopharmaceuticals Ltd., Hadasit Medical Research Services
    Inventors: Iris Pecker, Israel Vlodavsky, Yael Friedmann, Tuvia Peretz
  • Publication number: 20080248020
    Abstract: The invention relates to novel heparanases, heparanase splice variants, and to polynucleotides encoding them. Particularly, the invention relates to Spalax heparanases, and to Spalax and human heparanase splice variants. Heparanase splice variants can be used, for example, to modulate the activity of heparanase in diseases disorders or conditions caused by or associated with the enzymatic activity of heparanase. For instance, a splice variant capable of down regulating the activity of heparanase can be used to treat primary tumors and/or to prevent or treat metastasis.
    Type: Application
    Filed: September 20, 2006
    Publication date: October 9, 2008
    Applicant: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
    Inventors: Nicola J. Nasser, Aaron Avivi, Israel Vlodavsky, Eviatar Nevo